(Q37564531)

21 August 2017

1 reference

title

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? (English)

1 reference

21 August 2017

0 references

1 reference

Alessandra Lugaresi

1

1 reference

PubMed ID

19637982

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Drug Delivery

21 August 2017

1 reference

21 August 2017

6

1 reference

21 August 2017

9

1 reference

21 August 2017

995-1002

1 reference

Assessing the validity of self-reported medication adherence in hepatitis C treatment.

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

A systematic review of adherence with medications for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Factors that influence adherence with disease-modifying therapy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Compliance, adherence, and the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Improving compliance with interferon-beta therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Lipoatrophy in patients with multiple sclerosis on glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Managing the adverse effects of interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Interferons and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Disease-modifying therapy in multiple sclerosis: strategies for optimizing management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Patient satisfaction with an injection device for multiple sclerosis treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

The J-Tip Needle-Free Injection System in controlled ovarian hyperstimulation in in vitro fertilization: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903134769

10.1517/17425240903134769

21 January 2018

Identifiers

DOI

1 reference

release_zqonzglg35bjbkuh34sffc67a4

21 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zqonzglg35bjbkuh34sffc67a4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19637982

1 reference

PubMed ID

19637982